Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Relapsed/refractory (R/R) disease is a major hurdle to long‐term survival of acute myeloid leukemia (AML) patients treated with intensive cytarabine (AraC)‐based chemotherapy. R/R AML salvage treatment with venetoclax (VEN) + azacitidine (AZA) results in overall response rates between 20% and 60%, a...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2026-02-01
Serie:	Molecular Oncology
Soggetti:	acute myeloid leukemia azacitidine AZD4573 venetoclax
Accesso online:	https://doi.org/10.1002/1878-0261.70124
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!